PSA Testing & Prostate Monitoring While on TRT

Last Updated: OCTOBER 2023

Men with prostate cancer undergoing active surveillance who present with low testosterone levels (e.g., below 300 ng/dL) may face a higher risk of disease progression to a more aggressive form, according to a study by Shore et al. published in European Urology in 2014. This finding challenges long-held assumptions about testosterone’s role in prostate health. For too long, fear of prostate cancer has been a primary barrier to optimizing testosterone levels. The evidence increasingly suggests that appropriately managed testosterone replacement therapy (TRT) does not inherently cause prostate cancer or worsen outcomes in men without pre-existing disease. Instead,